复星医药：酮洛芬贴剂获临床试验批准

Core Viewpoint - Fosun Pharma (600196.SH) announced that its subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for the drug Ketorolac patch [1] Group 1 - The approval allows Chaohui Pharmaceutical to initiate Phase III clinical trials for the Ketorolac patch in China once conditions are met [1]